Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Non-Current Liabilities (2018 - 2023)

Historic Total Non-Current Liabilities for China Pharma Holdings (CPHI) over the last 12 years, with Q1 2023 value amounting to $10.5 million.

  • China Pharma Holdings' Total Non-Current Liabilities changed N/A to $10.5 million in Q1 2023 from the same period last year, while for Mar 2023 it was $10.5 million, marking a year-over-year change of. This contributed to the annual value of $11.1 million for FY2022, which is 2470.65% down from last year.
  • Per China Pharma Holdings' latest filing, its Total Non-Current Liabilities stood at $10.5 million for Q1 2023.
  • China Pharma Holdings' 5-year Total Non-Current Liabilities high stood at $14.7 million for Q4 2021, and its period low was $9.6 million during Q3 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $10.5 million (2023), whereas its average is $11.0 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first soared by 4228.04% in 2021, then tumbled by 2470.65% in 2022.
  • Quarter analysis of 5 years shows China Pharma Holdings' Total Non-Current Liabilities stood at $10.6 million in 2019, then dropped by 2.18% to $10.4 million in 2020, then skyrocketed by 42.28% to $14.7 million in 2021, then decreased by 24.71% to $11.1 million in 2022, then dropped by 5.3% to $10.5 million in 2023.
  • Its Total Non-Current Liabilities stands at $10.5 million for Q1 2023, versus $11.1 million for Q4 2022 and $14.7 million for Q4 2021.